Qualigen, a privately-held company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, completed the merger with Ritter Pharmaceuticals, which develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, in an all-stock deal. "The time is right for us to take advantage of our core science and regulatory experience from our diagnostic business and expand into promising cancer therapeutic drugs and devices. With this transaction and our key knowledge in cancer and infectious disease, we look forward to progressing our clinical development programs," Michael S. Poirier, President, Qualigen CEO and Chairman.